Anaheim, California Clinical Trials

A listing of Anaheim, California clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 50 clinical trials
Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

Primary Objective: To confirm appropriate dose levels of fitusiran when administered to male pediatric participants (ages 1 to <12 years of age) with severe hemophilia A or B Secondary Objective: To characterize the safety and tolerability To characterize the pharmacokinetics (PK)

fitusiran
haemophilia a
bethesda assay
factor ix
hemophilia
Investigational Site Number 8400010
 (4.1 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +10 other locations
Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B With or Without Inhibitory Antibodies to Factor VIII or IX

Primary Objective: To characterize the long-term safety and tolerability of fitusiran Secondary Objectives: To characterize the long-term efficacy of fitusiran as assessed by the frequency of: Bleeding episodes Spontaneous bleeding episodes Target joint bleeding episodes To characterize the effects of fitusiran on health-related quality of life (HRQOL) measures in participants …

fitusiran
haemophilia a
hemophilia
antihemophilic factor
hemarthrosis
Investigational Site Number 8400016
 (4.1 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +43 other locations
Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

Primary Objective: To confirm appropriate dose levels of fitusiran when administered to male pediatric participants (ages 1 to <12 years of age) with severe hemophilia A or B Secondary Objective: To characterize the safety and tolerability To characterize the pharmacokinetics (PK)

fitusiran
haemophilia a
bethesda assay
factor ix
hemophilia
Investigational Site Number 8400010
 (4.1 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +10 other locations
A Study to Evaluate the Efficacy and Safety of Frexalimab, SAR442970, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease (RESULT)

This is a parallel, Phase 2a, double-blind, 6-arm study for the treatment of primary focal segmental glomerulosclerosis (FSGS) or primary minimal change disease (MCD).The purpose of this study is to measure the change in proteinuria and its impact on the rates of remission of nephrotic syndrome with frexalimab, SAR442970, or …

Investigational Site Number : 8400015
 (4.1 away) Contact site
  • 0 views
  • 20 Jun, 2025
  • +24 other locations
A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression

Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. It is the most common form of lung cancer, accounting for around 85% of lung cancers. The purpose of this study is to evaluate the safety and efficacy …

measurable disease
cancer
venetoclax
anaplastic lymphoma
lung cancer
Icri /Id# 217071
 (8.7 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +38 other locations
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

This is a Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of AB928-based combination therapy in participants with metastatic castrate resistant prostate cancer (mCRPC).

measurable disease
taxane
castration-resistant prostate cancer
cancer
prostatic neoplasm
The University of California, Irvine Medical Center
 (4.1 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +21 other locations
A Study of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects

This is a randomized, single-blind, placebo-controlled, once daily (QD) dose study of CRV431 in presumed NASH F2/F3 subjects.

hepatic fibrosis
fibroscan
fatty liver
fibrosis
vcte
Conquest Clinical Research
 (5.4 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +9 other locations
Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne

The purpose of the trial is to evaluate the safety, efficacy and immunogenicity of up to 3 intramuscular injections of the Acne mRNA vaccine candidate at up to three dose levels in adult participants aged 18 to 45 years with moderate to severe acne. This trial will consist of a …

Core Healthcare Group- Site Number : 8400067
 (8.7 away) Contact site
  • 0 views
  • 29 Nov, 2025
  • +30 other locations
Development and Analysis of a Stool Bank for Cancer Patients

This study is aimed at understanding the impact of gut microbiota on efficacy of cancer therapies, in particular checkpoint inhibitors, and using the resulting information to design microbial immunotherapies. Although animal models are of use to determine the influences of gut and other microbiota on cancer treatment modalities, they are …

pembrolizumab
cancer treatment
immunotherapies
cancer immunotherapy
Compassionate Care Research Group, Inc.
 (8.7 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +1 other locations
Patient-Derived Xenografts to Reduce Cancer Health Disparities

This trial establishes patient-derived cancer xenografts in addressing cancer health and treatment disparities that disproportionately affect racial/ethnic minorities. Understanding the genetic and response differences among racial/ethnic minorities may help researchers enhance the precision of therapeutic treatments.

liver cancer
cancer
biospecimen collection
lung cancer
bladder cancer
UC Irvine Health/Chao Family Comprehensive Cancer Center
 (4.1 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +1 other locations